In adults with type 2 diabetes at moderate cardiovascular risk, semaglutide was associated with lower MACE risk than dulaglutide (HR 0.85, 95% CI 0.78 to 0.93).
In plain wordsIn adults with type 2 diabetes at moderate cardiovascular risk, semaglutide was linked to lower major cardiovascular event risk than dulaglutide.
- Peptide
- Semaglutide
- Outcome
- DecreaseMajor adverse cardiovascular events
- Study
n = 68,635
- Comparator
- Dulaglutide
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- Hazard ratio
- 0.85
- native drug versus dulaglutide
- 95% CI
- 0.78 to 0.93
- reported IPTW comparison
Source sentences
semaglutide was associated with lower risk of MACE (HR 0.85, 95CI % 0.78-0.93), expanded MACE (HR 0.92, 95CI % 0.87-0.96), all-cause mortality (HR 0.81, 95CI % 0.71-0.92), stroke (HR 0.82, 95CI % 0.70-0.97), and revascularization (HR 0.93, 95CI % 0.88-0.99)
5 context sentences(design, population, supporting numbers)
Compared to dulaglutide
We emulated a target trial using claims data of adults with T2D at moderate cardiovascular risk who initiated dulaglutide, exenatide, liraglutide, or semaglutide between 01/01/2014-12/31/2021.
Random treatment assignment was emulated by propensity scores and incorporated into inverse probability of treatment weighted (IPTW) Cox models.
Outcomes were time to composite major adverse cardiovascular events (MACE: myocardial infarction, stroke, and all-cause mortality), expanded MACE (MACE, hospitalization for heart failure, and revascularization) and its components, and severe hypoglycemia.
After IPTW, 35,572 patients initiated dulaglutide, 4376 initiated exenatide, 8843 initiated liraglutide, and 33,063 initiated semaglutide.